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ABSTRACT
Objective: To identify a treatment-responsive BRAFV600E mutation in brainstem neurohistiocyto-
sis, where no lesional tissue was readily obtainable, using a cell-free DNA approach.
Methods: Cell-free DNA was extracted from urine and allele-specific PCR for the BRAFV600E
mutation was performed. Response to conventional treatment (corticosteroids and
interferon) and targeted treatment with a BRAF inhibitor was assessed by clinical evaluation,
gadolinium-enhanced MRI brain scan, and serial testing of urinary cell-free DNA for mutant
alleles.
Results: BRAFV600E mutation could be readily identified in urinary cell-free DNA at an allele fre-
quency of 4.2%. Treatment of Erdheim-Chester disease with corticosteroids and interferon was
ineffective and associated with disease progression. Treatment with BRAF inhibitors was asso-
ciated with clinical improvement and near-complete radiologic remission. Following 6 months of
BRAF inhibitor therapy, no enhancing lesions could be detected in the brain and mutant alleles
were cleared from the urine.
Conclusions: Analysis of urinary cell-free DNA using allele-specific PCR for BRAFV600E mutations
allows rapid noninvasive identification of a highly treatment-responsive pathway, leading to clin-
ical and radiologic remission of disease. Our case demonstrates that this assay may have a par-
ticular role in challenging neurohistiocytosis cases, where attempts at obtaining lesional tissue
have failed or are not feasible.
Classification of evidence: This study provides Class IV evidence. This is a single observa-
tion study without controls. Neurol Neuroimmunol Neuroinflamm 2017;4:e299; doi: 10.1212/
NXI.0000000000000299
GLOSSARY
ECD 5 Erdheim-Chester disease.
Erdheim-Chester disease (ECD) is a neurotropic histiocytic disorder that can present with
isolated CNS disease. As such, it is difficult to diagnose and can mimic diseases such as mul-
tiple sclerosis1 and other neuroinflammatory diseases.2 CNS involvement often has a pre-
disposition for deep sites, affecting the brainstem and cerebellum.3 Involvement of the CNS
confers a poor prognosis with conventional immunomodulatory therapy and is often refrac-
tory to treatment.4
Recent studies have shown that ECD is a proliferative disorder of the myeloid lineage, with
a high frequency of somatic BRAFV600E mutations.5 These findings present the possibility of
making a molecular diagnosis and using targeted therapies, sometimes with dramatic benefit.6–8
However, identification of such mutations requires the extraction of DNA from lesional tissue.
In patients with deep-seated brainstem disease, this may not be an option.4 Even when multi-
system disease is present, bone biopsy is often highly fibrotic and may not be adequately
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enriched for somatic mutation or yield DNA
of sufficient quality.3 A recent report has high-
lighted the potential utility of cell-free DNA to
deliver an accurate molecular diagnosis in his-
tiocytosis.9 Cell-free DNA is released by dis-
eased cells into the bloodstream and filtered
into the urine, where it can be purified and
analyzed for the presence of mutant alleles.9
We demonstrate that a highly treatment-
responsive BRAFV600E mutation can be iden-
tified by a simple and rapid urine cell-free
DNA test in a particularly challenging
CNS ECD case, where lesional tissue could
not be readily obtained. The identification of
the mutation predicted a near-complete
response of brain lesions to BRAF inhibition
after the failure of conventional therapy.
CASE REPORT A 62-year-old man presented with
polydipsia and cranial diabetes insipidus, associated
with an isolated pituitary stalk lesion (figure 1A).
At presentation, there were no neurologic symp-
toms and examination was normal. CT scan of
the whole body was normal. The patient was kept
under clinical and radiologic observation. Over 4
years, he developed gradually progressive bilateral
facial numbness, difficulty with visual tracking, and
dysarthria. Examination showed evidence of bilat-
eral sensory trigeminal neuropathy, impaired sac-
cadic eye movements, mild dysarthria, and
intention tremor. Serial MRI of the brain showed
development of multiple persistently enhancing le-
sions, distributed predominantly throughout the
pons and cerebellum (figure 1, B, D, and E). CSF
examination was unremarkable, with no oligoclonal
bands, no erythrocytes or leukocytes, and normal
protein. Bone marrow biopsy was normal. A repeat
whole body CT showed a new single sclerotic lesion
within the L2 vertebra, with nonspecific findings
on biopsy (figure 1C). Bone scan revealed abnormal
uptake in distal limb bones (figure 1F). The patient
was referred to a national histiocytosis care center
and a clinical radiologic diagnosis of ECD was
made. The patient received conventional therapy
with corticosteroids and interferon-a, with no clin-
ical benefit.
In light of recent evidence suggesting a possible
role for BRAF inhibition in the treatment of histio-
cytic disorders,6 options for obtaining biopsy material
to look for BRAFV600E mutation were reviewed. Given
the deep location of the brain lesions, the risk of brain
biopsy was considered high. Two biopsies of bone
Figure 1 Clinical–radiologic diagnosis of Erdheim-Chester disease
(A) Isolated infundibular lesion (arrow) causing diabetes insipidus at presentation. (B) Gadolinium-enhancedMRI scan of the brain; axial sections through pons
show multiple enhancing lesions. (C) CT scan of spine shows isolated vertebral sclerotic lesion (biopsy shown was negative for lesional tissue). (D) Sagittal
fluid-attenuated inversion recovery MRI of brain shows lesions distributed throughout the pons and cerebellum. (E) Enhancing lesion in cauda equina (white
arrow). (F) Bone scan shows characteristic uptake in the long bones (femur, tibia).
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revealed no lesional tissue (table e-1 at Neurology.
org/nn). The lack of other involved organs presented
little option for obtaining fresh lesional material in
which to identify targetable kinase mutations. We
therefore performed allele-specific BRAFV600E PCR
on urine and peripheral blood.9
Figure 2 Detection of BRAFV600E mutation in urine cell-free DNA from a patient with brainstem
Erdheim-Chester disease and subsequent response to targeted treatment with dabrafenib
(A) Overview of urine cell-free DNA extraction and allele-specific PCR forBRAFV600Emutation. (B)BRAFV600Emutation detected
by allele-specific PCR from urine cell-free DNA. Red bars: cfDNA extracted from urine and plasma prior to therapy; gray bars:
controls 0%, 0.1%, 10%, and 100%; purple bars: DNA from fresh tibial biopsy (see figure 3). (C) Serial evaluation of gado-
linium (Gd)–enhancing brain lesions on MRI brain scan, with conventional treatment (S1/2 5 pulsed IV methylprednisolone
1 g/oral prednisolone 40mg2months; I5 recombinant interferon-a: s/c Pegasys 180 mg/wk for 6 months) and BRAF inhibitor
(dabrafenib 150mg bd, ongoing treatment). (D) MRI brain before treatment with dabrafenib: axial T1Gd-enhancedMRI scan of
brain and pons with corresponding T2 sequences (lower). (E) MRI brain after treatment with dabrafenib axial T1 gadolinium-
enhanced MRI scan of brain and pons with corresponding T2 sequences (lower). Near-complete resolution of Gd-enhancing
lesions is shown, with corresponding reduction in T2 lesion load. POQR 5 positive outside quantitative range.
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METHODS Cell-free DNA was extracted from urine and
plasma using QIAamp DNA micro and circulating nucleic acid
kits (Qiagen; Venlo, Netherlands) and subjected to allele-
specific PCR using a BRAFV600E Taqman Detection Assay (Life
Technologies, Nærum,Denmark; figure 2A for overview). DNA
from BRAFV600E melanoma cell line a375 (American Type Culture
Collection) diluted into EBV-transformed B cells was used as
a positive control. The clinical response to BRAF inhibition was
monitored through clinical assessment, serial gadolinium MRI
scan of the brain, and detection of mutant alleles in the urine
using the urine cell-free DNA assay described above.
RESULTS Urine cell-free DNA was positive with
4.2% BRAFV600E alleles (figure 2B). Peripheral
blood mononuclear cell and cell-free DNA gave
indeterminate or negative results (figure 2B).
Prior to identification of the BRAFV600E mutation,
the patient was treated with corticosteroids and then
recombinant interferon-a therapy (Pegasys 180 mg/
wk for 6 months), which is used as first-line therapy
for ECD. The patient reported progression of brain-
stem symptoms during this time and his radiologic
appearances worsened (figure 2C).
After detection of BRAFV600E mutation in urine,
the patient was started on an oral BRAF inhibitor
(vemurafenib 960 mg bd) but developed moderately
severe liver toxicity within 2 weeks of starting
Figure 3 Allele-specific PCR for BRAFV600E mutation from urine cell-free DNA is a possible biomarker of
neurologic disease activity
(A) Urine allele-specific PCR was monitored during treatment with BRAF inhibitors and correlated with MRI brain lesion
load (gadolinium-enhancing lesions). The presence of the BRAFV600E mutation was finally confirmed from lesional tissue
obtained from surgical tibial biopsy. (B) CT-PET shows disease activity in both tibiae. (C–E) Tibial bone biopsy shows
a diffuse infiltrate of foamy mononuclear macrophages (hematoxylin & eosin), which express CD68 and CD163 but not
CD1a. DNA was extracted from fresh bone biopsy and was positive for BRAFV600E mutation. Scale bars: C 5 1 mm, D 5
100 mm, E 5 100 mm.
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treatment and was changed to dabrafenib 150 mg bd.
Dabrafenib, an alternative oral BRAF inhibitor, was
tolerated well. Within a month of starting treatment
with BRAF inhibitors, the patient experienced reso-
lution of dysarthria and saccadic abnormalities. His
use of nocturnal desmopressin spray halved. At 3
months of treatment, MRI scan of the brain showed
.90% reduction in enhancing lesions with a concom-
itant 90% reduction in urinary mutant allele count
(figures 2, D and E, and 3A). At 6 months of treat-
ment there were no enhancing lesions on MRI brain
and BRAFV600E allele count was undetectable in urine
(figure 3A). Clinical and radiologic response has been
sustained at 1 year.
Confirmation of the molecular diagnosis was
eventually obtained from a surgical tibial bone biopsy
that was analyzed fresh (figures 2B and 3, B–E, and
table e-1). Histologic findings confirmed the presence
of foamy macrophages and CD1631/CD681/
CD1a-cells, consistent with a diagnosis of ECD.
DISCUSSION Histiocytic disorders presenting with
isolated CNS disease are an important differential
diagnosis of multiple sclerosis10 and other neuro-
inflammatory/infiltrative disease.2,11 Such presen-
tations are associated with a poor response to
standard therapy.4 The recent identification of tar-
getable somatic BRAF mutations in these disorders
highlights the potential benefit for patients with
these challenging orphan diseases. However, if this
potentially transformative therapeutic approach is
to be exploited, lesional tissue is required, which we
show here can present a major challenge to clini-
cians. Even when lesional tissue can be obtained
from bone, identification of mutant DNA can fail
since bone lesions can be highly fibrotic and cellu-
lar content low.3,9
We show that a simple rapid noninvasive urine
test can guide treatment with a highly effective tar-
geted therapy for deep neurohistiocytosis, where
standard therapy has failed. In this case, this test
reliably identified a somatic BRAFV600E mutation
where multiple invasive approaches to obtaining
lesional tissue had failed. The identification of this
mutation identified a near-complete response to
BRAF inhibition, in contrast to conventional ther-
apy, which had been associated with relentless dis-
ease progression. This neuroradiologic response
was observed across all brain MRI sequences used
to assess disease activity, including T1 with con-
trast, T2, and fluid-attenuated inversion recovery,
and was associated with clinical improvement.
Importantly, the mutated allele frequency de-
tected in the urine correlated with clinical and
radiologic responses, suggesting that this may pro-
vide a further noninvasive modality for monitoring
response to therapy. This may be particularly
important in ECD, where repeat bone biopsy to
monitor disease activity may be challenging
because of its invasive nature and lack of reliable
involvement.3
In this case, urine cell-free DNA testing for
BRAFV600E was at least as sensitive as fresh lesional
DNA. Our case also shows that although treatment
with vemurafenib can cause sufficiently serious liver
toxicity to lead to discontinuation of the drug, alter-
native BRAF inhibitors remain an efficacious option
in patients with a somatic BRAF mutation.
Therefore, urine cell-free DNA presents an option
to diagnose and monitor actionable somatic muta-
tions in neurohistiocytic disorders, especially when le-
sional tissue is not readily available.
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